Siemens has announced plans to reduce its ownership in Siemens Healthineers, shifting from a controlling stake to a significant minority interest. The company stated that this move is intended to provide greater flexibility in capital allocation while allowing Siemens to continue participating as a minority shareholder in Siemens Healthineers' business.
According to the company, the medium-term goal is to further reduce its holding so that it is considered a financial asset. Siemens emphasized its commitment to managing this investment responsibly and with a focus on shareholders. The company also reaffirmed that its progressive dividend policy will remain unchanged following the deconsolidation of Siemens Healthineers.
Roland Busch, President and Chief Executive Officer of Siemens AG, said: “Today marks the beginning of the next stage of growth for Siemens. By giving up the controlling majority in Siemens Healthineers, we are focusing on a highly synergistic Siemens portfolio. This is a logical next step in executing our strategy of combining the real and the digital worlds, focusing on accelerated profitable growth of our digital businesses, connected and software defined hardware and industrial AI.”
Ralf P. Thomas, Chief Financial Officer of Siemens AG, added: “Each of the two companies has a strong financial profile offering strategic flexibility to accelerate value creation in their respective core markets through tailored capital allocation – enabling both organizations to operate with greater agility and focus. For Siemens, the deconsolidation gives additional leeway, increases transparency while reducing complexity for the capital market, and simplifies governance structures. At the same time, the way of spin-off is a market-friendly transfer of shares.”
The decision follows an assessment and strategic review aimed at helping both companies maximize their potential and tap into new areas for growth. The change is expected to sharpen Siemens’ identity as a technology-focused company and increase customer focus and innovation speed. For Siemens Healthineers, increased free float could enhance its appeal in capital markets as an independent medical technology firm.
The planned transaction requires final regulatory clarifications and approvals from shareholder meetings at both companies. In coming months, Siemens will work with stakeholders on structuring and scheduling the transaction, with more details expected by early Q2 2026.
Siemens also announced it will provide updates on its business performance and strategy at its upcoming “Siemens ONE Tech – Strategy & Results” event scheduled for November 13, 2025.